| Identification | More | [Name]
5-(Difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl) sulfinyl)-1H-benzimidazole sodium | [CAS]
138786-67-1 | [Synonyms]
5-(DIFLUOROMETHOXY)-2-[[(3,4-DIMETHOXY-2-PYRIDINYL)METHYL]SULFINYL]-1H-BENZIMIDAZOLE
5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl) sulfinyl)-1h-benzimidazole sodium
EUPANTOL
PANTECTA
PANTOPRAZOLE SODIUM
PANTOPRAZOLE SODIUM HYDRATE
PANTOPRAZOLE, SODIUM SALT
PANTOZOL
1h-benzimidazole,5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sul
5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-1h-benzi
midazolesodium
Eupantol, Pantecta, Pantozol, 5-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
PANTOPRAZOLE SODIUM MONOHYDRATE
Pantoprazole sodium(factory standard)
5-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridynyl)methyl]-1H-benzimidazol-1-ium sodium salt
Controloc
Pantoloc
Protonix
Sodium pantoprazole | [EINECS(EC#)]
604-093-4 | [Molecular Formula]
C16H14F2N3NaO4S | [MDL Number]
MFCD01658543 | [Molecular Weight]
405.35 | [MOL File]
138786-67-1.mol |
| Chemical Properties | Back Directory | [Appearance]
White to Off-White Solid | [Melting point ]
199-202°C | [storage temp. ]
Inert atmosphere,Store in freezer, under -20°C | [solubility ]
DMSO (Slightly), Methanol (Slightly, Sonicated), Water (Slightly) | [form ]
neat | [color ]
White to Pale Beige | [Usage]
An antiulcerative. Gastric pump inhibitor | [Stability:]
Hygroscopic | [InChI]
InChI=1S/C16H14F2N3O4S.Na/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16;/h3-7,15H,8H2,1-2H3;/q-1;+1 | [InChIKey]
YNWDKZIIWCEDEE-UHFFFAOYSA-N | [SMILES]
C12C=C(C=CC=1N(C(S(=O)CC1N=CC=C(OC)C=1OC)=N2)[Na])OC(F)F | [CAS DataBase Reference]
138786-67-1(CAS DataBase Reference) | [CAS Number Unlabeled]
138786-67-1 |
| Safety Data | Back Directory | [Symbol(GHS) ]
GHS07 | [Signal word ]
Warning | [Hazard statements ]
H302 | [Precautionary statements ]
P301+P312+P330 | [Hazard Codes ]
Xn | [Risk Statements ]
R20/21/22:Harmful by inhalation, in contact with skin and if swallowed .
R37/38:Irritating to respiratory system and skin .
R41:Risk of serious damage to eyes.
R48:Danger of serious damage to health by prolonged exposure. | [Safety Statements ]
S22:Do not breathe dust .
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection .
S45:In case of accident or if you feel unwell, seek medical advice immediately (show label where possible) . |
| Hazard Information | Back Directory | [Chemical Properties]
White to Off-White Solid | [Originator]
Controloc,Byk Gulden ,Germany | [Uses]
An antiulcerative. Gastric pump inhibitor | [Uses]
Gastrointestinal | [Definition]
ChEBI: Pantoprazole sodium is an organic sodium salt. It has a role as an EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor and an anti-ulcer drug. It contains a pantoprazole(1-). | [Manufacturing Process]
2-Chloromethyl-4,5-dimethoxy-3-methylpyridinium chloride (about 1.5 g) are added to a solution of 5-difluoromethoxy-1H-benzimidazole-2-thiol in 10 ml of ethanol and 10 ml of 1 N sodium hydroxide solution. The yellow reaction mixture is stirred at 20°C for 1 hour, a further 10 ml of water are added,
whereupon a colorless solid precipitates out, the mixture is stirred for a further 5 hours and filtered and the residue is rinsed with 1 N sodium hydroxide solution and water and dried to constant weight. The 5difluoromethoxy-2-[(4,5-dimethoxy-2-pyridyl)methylthio]-1H-benzimidazole is obtained as an oil.
5-Difluoromethoxy-2-[(4,5-dimethoxy-2-pyridyl)methylthio]-1H-benzimidazole (about 1 g) are dissolved in 10 ml of dioxane and 2 ml of 1 N sodium hydroxide solution. An equimolar amount of a titrated aqueous sodium hypochlorite solution, to which 1 mole per liter of sodium hydroxide solution has been added, is first added dropwise, while cooling with ice. After one hour a further equivalent and after 3 hours half the equimolar amount of sodium hypochlorite are added, to achieve complete reaction. After a reaction time of 4 hours, 5 ml of 5% strength sodium thiosulfate solution and another 25 ml of dioxane are added and the upper dioxane phase is separated off, washed once with 5 ml of sodium thiosulfate solution and concentrated on a rotary evaporator. The oily residue is dissolved in 20 ml of water and 10 ml of ethyl acetate and the solution is brought to pH 7 with about 100 ml of a buffer solution of pH 6.8. The solid which has precipitated out is filtered off with suction over a suction filter, washed with water, extracted by stirring at 0C with acetone and dried. 5-Difluoromethoxy-2-[(4,5-dimethoxy-2pyridyl)methanesulfinyl]-1H-benzimidazole is prepared; yield about 85%.
| [Brand name]
Protonix (Wyeth). | [Therapeutic Function]
Antiulcer | [General Description]
Pantoprazole sodium, racemicsodium5-(difluoromethoxy)-2-[[3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sesquihydrate is a white tooff-white crystalline powder that is freely soluble in water,very slightly soluble in phosphate buffer at pH 7.4, and practicallyinsoluble in n-hexane. The benzimidazole of this drughas a weakly basic nitrogen (pyridine N, pKa 3.83) and an benzimidazoleproton (pKa 0.11), facilitating formulation as asodium salt. The stability of the compound in aqueous solutionis pH dependent; the rate of degradation increases with decreasingpH. At ambient temperature, the degradation half-lifeis approximately 2.8 hours at pH 5.0 and approximately 220hours at pH 7.8.
The absorption of pantoprazole is rapid (Cmax of2.5μg/mL, Tmax 2.5 hours) after single or multiple oral40-mg doses. Pantoprazole is well absorbed (77% bioavailability).Administration with food may delay its absorptionbut does not alter pantoprazole bioavailability. Pantoprazoleis distributed mainly in extracellular fluid. The serum proteinbinding of pantoprazole is about 98%, primarily to albumin.Pantoprazole is extensively metabolized in the liver throughthe CYP system, including O-demethylation (CYP2C19),with subsequent sulfation. Other metabolic pathways includesulfur oxidation by CYP3A4. There is no evidencethat any of the pantoprazole metabolites have significantpharmacological activity. Approximately 71% of a dose of pantoprazole is excreted in the urine, with 18% excretedin the feces through biliary excretion. | [Biological Activity]
Gastric proton pump inhibitor. It is used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease. | [storage]
4°C, protect from light | [References]
[1] Patent: WO2004/111029, 2004, A2. Location in patent: Page 24
[2] Patent: CN107011252, 2017, A. Location in patent: Paragraph 0101; 0103
[3] Patent: WO2004/111029, 2004, A2. Location in patent: Page 24
[4] Patent: WO2009/75516, 2009, A2. Location in patent: Page/Page column 5
[5] Patent: WO2004/111029, 2004, A2. Location in patent: Page 24 |
|
| Company Name: |
J & K SCIENTIFIC LTD.
|
| Telephone: |
18210857532 18210857532 |
| Website: |
https://www.jkchemical.com |
|